Central retinal vein occlusion (CRVO) is a common problem encountered in general ophthalmology and retina clinics worldwide. Macular edema can result from abnormal vascular permeability due to CRVO and lead to substantial vision loss in some patients if left untreated. Over the last decade, multiple clinical trials have established the efficacy of intravitreous anti–vascular endothelial growth factor (VEGF) therapy for improving visual acuity with CRVO. However, it has been largely unclear which, if any, of the available anti-VEGF agents provides the best functional or anatomic outcomes. Given substantial differences in cost and availability between anti-VEGF drugs, a rigorous comparison of efficacy and safety among the most widely used agents has major implications for both individual patient treatment decisions and public health policy.
Sun JK. Comparing Anti–Vascular Endothelial Growth Factor Therapies for Central Retinal Vein Occlusion. JAMA Ophthalmol. 2017;135(6):649–650. doi:10.1001/jamaophthalmol.2017.1142
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: